000292119 001__ 292119
000292119 005__ 20250815134749.0
000292119 0247_ $$2doi$$a10.1016/j.gde.2024.102242
000292119 0247_ $$2pmid$$apmid:39111230
000292119 0247_ $$2ISSN$$a0959-437X
000292119 0247_ $$2ISSN$$a1879-0380
000292119 037__ $$aDKFZ-2024-01618
000292119 041__ $$aEnglish
000292119 082__ $$a610
000292119 1001_ $$0P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea$$aKoch, Jonas$$b0$$eFirst author$$udkfz
000292119 245__ $$aRefining the role of N6-methyladenosine in cancer.
000292119 260__ $$aAmsterdam$$bElsevier$$c2024
000292119 3367_ $$2DRIVER$$aarticle
000292119 3367_ $$2DataCite$$aOutput Types/Journal article
000292119 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723122835_32133$$xReview Article
000292119 3367_ $$2BibTeX$$aARTICLE
000292119 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292119 3367_ $$00$$2EndNote$$aJournal Article
000292119 500__ $$a#EA:A130#LA:A130# / DKFZ-ZMBH Alliance
000292119 520__ $$aN6-methyladenosine (m6A) is the most abundant internal modification of eukaryotic mRNAs. m6A affects the fate of its targets in all aspects of the mRNA life cycle and has important roles in various physiological and pathophysiological processes. Aberrant m6A patterns have been observed in numerous cancers and appear closely linked to oncogenic phenotypes. However, most studies relied on antibody-dependent modification detection, which is known to suffer from important limitations. Novel, antibody-independent, quantitative approaches will be critical to investigate changes in the m6A landscape of cancers. Furthermore, pharmaceutical targeting of the m6A writer Methyltransferase-like 3 (METTL3) has demonstrated the potential to modulate cancer cell phenotypes. However, the enzyme also appears to be essential for the viability of healthy cells. Further refinement of therapeutic strategies is therefore needed to fully realize the potential of m6A-related cancer therapies.
000292119 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000292119 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292119 7001_ $$0P:(DE-He78)a8d53a8cdc716390a6cbacdead227143$$aLyko, Frank$$b1$$eLast author$$udkfz
000292119 773__ $$0PERI:(DE-600)2013031-4$$a10.1016/j.gde.2024.102242$$gVol. 88, p. 102242 -$$p102242$$tCurrent opinion in genetics & development$$v88$$x0959-437X$$y2024
000292119 8564_ $$uhttps://inrepo02.dkfz.de/record/292119/files/1-s2.0-S0959437X24000911-main.pdf
000292119 8564_ $$uhttps://inrepo02.dkfz.de/record/292119/files/1-s2.0-S0959437X24000911-main.pdf?subformat=pdfa$$xpdfa
000292119 909CO $$ooai:inrepo02.dkfz.de:292119$$pVDB
000292119 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292119 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8d53a8cdc716390a6cbacdead227143$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292119 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000292119 9141_ $$y2024
000292119 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000292119 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN GENET DEV : 2022$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000292119 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000292119 9202_ $$0I:(DE-He78)A130-20160331$$kA130$$lA130 Epigenetik$$x0
000292119 9200_ $$0I:(DE-He78)A130-20160331$$kA130$$lA130 Epigenetik$$x0
000292119 9201_ $$0I:(DE-He78)A130-20160331$$kA130$$lA130 Epigenetik$$x0
000292119 980__ $$ajournal
000292119 980__ $$aVDB
000292119 980__ $$aI:(DE-He78)A130-20160331
000292119 980__ $$aUNRESTRICTED